AGC Pharma Chemicals announces the appointment of Jun Kurihara as its new Chief Executive Officer, effective June 1, 2025. Kurihara, who currently serves as Executive Vice President, has extensive experience in the CDMO sector and has played a pivotal role in the company’s transformation and growth.
In addition to his broad experience in the CDMO sector, Kurihara has over nine years in the pharmaceutical industry, holding key positions at AGC Pharma Chemicals and previously at AstraZeneca. During his leadership at AGC Pharma Chemicals, he led strategic projects that enabled the plant to reach near-maximum operational capacity. His industry knowledge, combined with a strong background in business development and marketing, has established him as a key figure in the company’s global expansion.
Jun Kurihara, new CEO of AGC Pharma Chemicals, stated: “I am deeply honored by the opportunity to lead AGC Pharma Chemicals in this new phase. My goal is to strengthen the company’s position as a leading strategic partner in the CDMO sector, driving operational excellence, innovation, quality, and sustainable growth. I am grateful for the trust placed in me by the management and the team, and I reaffirm my commitment to work together with the AGC team to achieve our vision of being the first choice as a CDMO and our mission to improve people’s lives by providing our products and services with the highest quality”.
Meanwhile, Akihiro Kadokura, current CEO of AGC Pharma Chemicals, will assume the role of Senior Executive Advisor at AGC Life Science. Under his leadership, the company has made significant strides in establishing itself as a leading CDMO in Europe, driving investments, acquiring new strategic projects, and consolidating a culture of excellence and collaboration. His strategic vision and commitment to innovation have been key to the organization’s success, laying the groundwork for the future development of AGC Pharma Chemicals.
